Modular Medical, Inc. reported its financial results for the quarter ending September 30, 2025, revealing a net loss of $7.79 million, or $0.14 per share, consistent with the loss of $4.96 million, or $0.14 per share, reported in the same quarter of the previous year. For the six months ended September 30, 2025, the company incurred a net loss of $14.49 million compared to a loss of $9.09 million for the same period in 2024. The increase in losses is attributed to higher operating expenses, which totaled $14.63 million for the first half of 2025, up from $9.22 million in the prior year, driven primarily by increased research and development (R&D) and selling, general, and administrative (SG&A) costs.

The company's total assets decreased to $12.97 million as of September 30, 2025, down from $18.74 million at the end of the previous fiscal year. This decline was largely due to a reduction in cash and cash equivalents, which fell to $5.32 million from $13.10 million. Current liabilities also increased significantly, rising to $4.21 million from $1.66 million, reflecting higher accounts payable and accrued expenses. The accumulated deficit reached approximately $99.25 million, indicating ongoing financial challenges as the company continues to seek funding for its operations.

Strategically, Modular Medical has made significant advancements in its product development. The company received FDA clearance for its MODD1 insulin delivery pump in September 2024 and announced the first human use of the device in August 2025. Additionally, the company is preparing to launch its next-generation product, the Pivot, for which it submitted a 510(k) premarket notification to the FDA in November 2025. The company aims to commercialize the Pivot product in the first quarter of 2026, pending regulatory approval.

Operationally, Modular Medical has expanded its workforce, increasing its R&D employee headcount to 56 as of September 30, 2025, up from 42 a year earlier. This growth reflects the company's commitment to enhancing its product offerings and market presence. The company also reported a significant increase in R&D expenses, which rose by 55.3% to $10.73 million for the six months ended September 30, 2025, compared to $6.91 million in the prior year. SG&A expenses also increased by 69.2% to $3.91 million for the same period, driven by higher personnel and consulting costs.

Looking ahead, Modular Medical faces substantial challenges regarding its liquidity and ability to continue as a going concern. The company has raised approximately $4.7 million through financing activities in the first half of fiscal 2026, including a warrant inducement offering and sales under its at-the-market program. However, the company acknowledges that it will need to secure additional capital to support its ongoing operations and product development initiatives. The management has expressed concerns about the company's ability to maintain compliance with Nasdaq listing requirements, particularly regarding the minimum bid price for its common stock, which could impact its future financing options.

About Modular Medical, Inc.

Modular Medical, Inc. designs and develops innovative, user-friendly insulin pumps aimed at expanding access to diabetes management. Its core products, MODD1 and Pivot, are simplified, affordable patch pumps with advanced technology for both Type 1 and Type 2 diabetes patients. The company focuses on streamlining insulin delivery, reducing costs, and improving clinical outcomes through modernized, mass-manufacturable devices and strategic market entry.

This description was generated via AI from an annual report. Updated 9 months ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.